Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Neurorx Inc
Headquarters: Wilmington, DE, United States of America
Website: https://www.nrxpharma.com/
Year Founded: 2015
Status: Private
BioCentury | May 27, 2022
Management Tracks
Kwon to lead Alchemab as Treco departs
Plus Drew Young to head commercial at Anthos, NRx general counsel leaving
BioCentury | Feb 24, 2021
Product Development
Feb. 23 Quick Takes: Hold for bluebird; plus priority review for Pfizer’s TicoVac and updates from Taiho and NeuroRx
bluebird revealed late Wednesday in its 4Q20 earnings that FDA placed a clinical hold on its trials of LentiGlobin due to suspected unexpected serious adverse reactions in the Phase I/II HGB-206
BioCentury | Feb 24, 2021
Deals
Feb. 23 Quick Takes: BGI raises $300M, plus a $230M C round for Clover, Day One, Waksal’s Graviton, Asalyxa
BGI Genomics Co. Ltd. (SZSE:300676) raised RMB2 billion ($309 million) through the sale of 13.8 million shares at RMB145 in a private placement. Huatai Securities Co. Ltd. purchased 8.3 million
BioCentury | Feb 13, 2021
Product Development
Feb. 12 COVID Quick Takes: Actemra reduces mortality in RECOVERY trial; plus updates from AZ, CanSino, Celltrion, NeuroRx, CureVac and Moderna
While previous trials of Actemra tocilizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) failed to demonstrate a survival benefit for COVID-19 patients, the U.K. RECOVERY
BioCentury | Dec 15, 2020
Finance
Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more
Vida leads Locanabio’s $100M B roundLocanabio Inc. raised $100 million in a series B financing led by Vida Ventures, with participation from new investors RA Capital, Invus, Acuta Capital
BioCentury | Aug 6, 2020
Product Development
BioNTech testing separate mRNA vaccine variant in Chinese trial, closes supply deal with Canada
Plus data for Relief’s peptide, EUA for a saliva test and clinical plans for ImmunityBio’s vaccine
BioCentury | Oct 24, 2019
Financial News
Oct. 23 Financial Quick Takes: Alexion buyback; plus RAPT, NeuroRX and Oyster Point
BioCentury | Jan 11, 2019
Clinical News
NeuroRx's NRX-101 improves depression and suicidality in Phase II
Items per page:
1 - 9 of 9